• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
    • Why Immunogenicity Risk Assessment?
    • Why EpiVax?
  • About Us
    • Company History
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
The Two-faced T cell Epitope: Examining the Host-Microbe Interface with JanusMatrix

The Two-faced T cell Epitope: Examining the Host-Microbe Interface with JanusMatrix

by Adam | Oct 22, 2016

Side-stepping Regulatory T Cell-Mediated Evasion in Chronic Viral Infection to Build Better Vaccines

Side-stepping Regulatory T Cell-Mediated Evasion in Chronic Viral Infection to Build Better Vaccines

by Adam | Oct 21, 2016

Immunogenicity Analysis of Chinese Hamster Ovary (CHO) Host Cell Protein Contaminants in Therapeutic Protein Formulations

Immunogenicity Analysis of Chinese Hamster Ovary (CHO) Host Cell Protein Contaminants in Therapeutic Protein Formulations

by Adam | Oct 21, 2016

iVAX: An integrated toolkit for the selection and optimization of antigens and the design of epitope-driven vaccines

iVAX: An integrated toolkit for the selection and optimization of antigens and the design of epitope-driven vaccines

by Adam | Jul 27, 2016

Computational vaccine design, also known as computational vaccinology, encompasses epitope mapping, antigen selection and immunogen design using computational tools. The iVAX toolkit is an integrated set of tools that has been in development since 1998 by De Groot and...
Next Entries »

Recent Posts

  • EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services    
  • Replacing Animal Models with Human-Relevant New Approach Methodologies (NAMs) for Immunogenicity in Clinic
  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy

Recent Comments

  1. Homepage on Doing Well and Giving Back in December

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.